Congresswoman Speier to Join Numerate in Announcing U.S. Department of Defense Contract for Speeding Design of Biowarfare

SAN BRUNO, Calif.--(BUSINESS WIRE)-- Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to radically transform the drug design process, will announce the award of a three-year contract by the Department of Defense through its Transformational Medical Technologies (TMT) Program. Numerate may receive up to $6.75 million under this new Defense Threat Reduction Agency (DTRA) contract to extend its pioneering data-driven drug design approach, applying modern machine-learning methods similar to those employed by Google, Amazon and Netflix to rapidly design new drugs with optimized safety, efficacy and dosing convenience.

WHO:

    Congresswoman Jackie Speier
Jeremy Leffler, Bay Bio Chief Operating Officer
Guido Lanza, Numerate Chief Executive Officer
Nigel Duffy, Numerate Chief Technology Officer
 

WHAT:

Press conference announcing award of DTRA contract to Numerate
 

WHERE:

Numerate headquarters, 1150 Bayhill Drive, Suite 203, San Bruno, CA
 

WHEN:

Thursday, September 9, 2010, from 11:30 a.m. to 12 noon.
Presenters will provide brief overview of company technology, potential significance to healthcare industry, and importance of biotech innovation, both locally and nationally.

Background

Numerate is a privately held biotechnology company focused on making the drug design process more data-driven, efficient and predictable. Numerate’s technology platform combines advances in computer science and statistics with traditional medicinal chemistry approaches to address, in parallel, the factors that determine the success and failure of a drug candidate. Numerate applies this proprietary platform to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical, biotechnology, and academic fields. For more information, visit www.numerate.com.

For more information about the Defense Threat Reduction Agency and the Transformational Medical Technologies program, please visit www.dtra.mil and www.tmti-cbdefense.org.



CONTACT:

for Numerate, Inc.
Carole Melis, 650-342-5686
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.